Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL) Meeting Abstract

  

Authors:	Sermer, D. J.; Vardhana, S. A.; Ames, A.; Biggar, E.; Moskowitz, A. J.; Batlevi, C. L.; Caron, P.; Hamilton, A. M.; Moskowitz, C. H.; Matasar, M. J.; Zelenetz, A. D.; Horwitz, S. M.; Von Keudell, G.; Yahalom, J.; Rademaker, J.; Dogan, A.; Seshan, V. E.; Younes, A.
Abstract Title:	Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
Meeting Title:	56th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	38
Issue:	15 Suppl.
Meeting Dates:	2020 May 29-31
Meeting Location:	Virtual
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2020-05-20
Language:	English
ACCESSION:	WOS:000560368307378
PROVIDER:	wos
DOI:	10.1200/JCO.2020.38.15_suppl.e20018
Notes:	Meeting Abstract: e20018 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/179174